Abacavir/lamivudine/zidovudine

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Abacavir/lamivudine/zidovudine
175px
Combination of
Abacavir Nucleotide analogue reverse transcriptase inhibitor
Lamivudine Nucleoside analogue reverse transcriptase inhibitor
Zidovudine Nucleoside analogue reverse transcriptase inhibitor
Clinical data
Trade names Trizivir
AHFS/Drugs.com FDA Professional Drug Information
MedlinePlus a687007
Pregnancy
category
  • US: C (Risk not ruled out)
Legal status
Routes of
administration		 Oral
Identifiers
CAS Number 364057-50-1 N
ATC code J05AR04 (WHO)
ChemSpider 21106400 YesY
NIAID ChemDB 058986
 NYesY (what is this?)  (verify)

Abacavir/lamivudine/zidovudine (INNs, trade name Trizivir) is a pharmaceutical treatment for HIV infection.[1] It is a fixed dose combination of three reverse transcriptase inhibitors patented by GlaxoSmithKline and now marketed by its joint venture with Pfizer, ViiV Healthcare:[2]

It is indicated in the treatment of AIDS/HIV.[3] For this purpose, the combination is very useful in pregnant women to decrease the risk of mother-to-child transmission.[4]

The combination of drugs helps to reduce HIV's resistance (through mutation) to the drugs individually. Of the three, AZT and ABC have passed out of United States patent protection.

In December 2013, Lupin Limited launched a generic version of Trizivir. [5][6]

See Also

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ InPharm.com: GlaxoSmithKline-Pfizer launch HIV joint venture
  3. ↑ Drugs.com: Trizivir
  4. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  5. ↑ Monthly Prescribing Reference (MPR): [1]
  6. ↑ Lupin Pharma: [2]


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Abacavir/lamivudine/zidovudine&oldid=2756769"